£¨Öйú£¬£¬£¬£¬£¬£¬ÉϺ££©
ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾¿­ÌØÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾½ñÈÕÐû²¼£¬£¬£¬£¬£¬£¬¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨NMPA£©ÒÑÕýʽ½«¹«Ë¾CD19°Ðµã×ÔÌåCAR-Tϸ°ûÖÎÁƲúÆ·°¢»ùÂØÈü×¢ÉäÒºµÄÐÂÔö˳Ӧ֢ÄÉÈëÍ»ÆÆÐÔÖÎÁÆÒ©Îï³ÌÐò£¬£¬£¬£¬£¬£¬Öƶ©Ë³Ó¦Ö¢ÎªÖÎÁƽÓÊܹý¶þÏß»òÒÔÉÏϵͳÐÔÖÎÁƺ󸴷¢»òÄÑÖÎÐÔ¶èÐÔ·Ç»ôÆæ½ðÁÜ°ÍÁö£¨r/r iNHL£©£¬£¬£¬£¬£¬£¬°üÀ¨ÂËÅÝÐÔÁÜ°ÍÁö£¨FL£©ºÍ±ßÑØÇøÁÜ°ÍÁö£¨MZL£©¡£¡£¡£¡£¡£¡£

ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾¿­ÌØCEO»Æº£ÏÈÉúÌåÏÖ£º¡°°¢»ùÂØÈü×¢ÉäÒº±»ÄÉÈëÍ»ÆÆÐÔÖÎÁÆÒ©Îï³ÌÐò£¬£¬£¬£¬£¬£¬ËµÃ÷ÎúNMPA¶ÔÒÔÁÙ´²¼ÛֵΪµ¼ÏòµÄÒ©ÎïÁ¢ÒìµÄÖ§³Ö£¬£¬£¬£¬£¬£¬Ò²Åú×¢Îú¸Ã¿îÒ©ÎïÔÚÖÎÁƸ´·¢»òÄÑÖÎÐÔ¶èÐÔ·Ç»ôÆæ½ðÁÜ°ÍÁöµÄÁÙ´²ÓÅÊƺÍDZÁ¦¡£¡£¡£¡£¡£¡£¹«Ë¾½«¼ÓËÙ¸ÃÒ©ÎïÐÂ˳Ӧ֢µÄÁÙ´²½×¶ÎÀú³Ì£¬£¬£¬£¬£¬£¬Æð¾¢×Ô¶¯µØÓëÒ©Æ·ÉóÆÀÖÐÐľÙÐÐÏàͬºÍ½»Á÷£¬£¬£¬£¬£¬£¬¾¡¿ìΪÖйú¸ü¶à·Ç»ôÆæ½ðÁÜ°ÍÁö»¼Õß´øÀ´ÐÂÉúµÄÏ£ÍûºÍʱ»ú¡£¡£¡£¡£¡£¡£¡±

¹ØÓÚ¶èÐÔ·Ç»ôÆæ½ðÁÜ°ÍÁö

¶èÐÔ·Ç»ôÆæ½ðÁÜ°ÍÁö£¨iNHL£©ÊÇÁÙ´²Ï£Íû»ºÂý£¬£¬£¬£¬£¬£¬µ«Ëæ×Åʱ¼äÍÆÒÆ»á±äµÃ¸ü¾ßÇÖÏ®ÐԵĶñÐÔÖ×Áö¡£¡£¡£¡£¡£¡£ÂËÅÝÐÔÁÜ°ÍÁö£¨FL£©ºÍ±ßÑØÇøÁÜ°ÍÁö£¨MZL£©¶¼ÊÇÆä³£¼ûÑÇÐÍ¡£¡£¡£¡£¡£¡£FLÒ²ÊÇÈ«ÇòµÚ¶þ´ó³£¼ûµÄÁÜ°ÍÁöÀàÐÍ£¬£¬£¬£¬£¬£¬Ô¼Õ¼È«ÇòNHLÈ·ÕﲡÀýµÄ22£¥¡£¡£¡£¡£¡£¡£MZLÊǵÚÈý´ó³£¼ûÁÜ°ÍÁö£¬£¬£¬£¬£¬£¬Ô¼Õ¼ËùÓÐBϸ°ûNHLµÄ8£¥ÖÁ12£¥1¡£¡£¡£¡£¡£¡£ËäÈ»Ëæ׿²²¡ÖÎÀíµÄÇ°½ø£¬£¬£¬£¬£¬£¬FL»¼Õߺã¾ÃÉúÑÄÂÊÓÐÁ˺ܴóÌá¸ß£¬£¬£¬£¬£¬£¬µ«Ô¤ºóÈ´±£´æºÜ´ó²î±ð¡£¡£¡£¡£¡£¡£ÏÖÔÚ¹ØÓÚ¾­ÓɶþÏß¼°ÒÔÉÏÖÎÁƺ󸴷¢ºÍÄÑÖεÄFL»¼ÕßÉÐÎÞ±ê×¼ÖÎÁƼƻ®£¬£¬£¬£¬£¬£¬¸´¾ÙÊÂÖεÄMZL»¼ÕßÖÎÁÆÑ¡ÔñÒ²ºÜÊÇÓÐÏÞ¡£¡£¡£¡£¡£¡£

¹ØÓÚ°¢»ùÂØÈü×¢ÉäÒº

°¢»ùÂØÈü×¢ÉäÒºÊÇÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾¿­ÌØ2017ÄêÍ·´ÓÃÀ¹úKite£¨ÏéÈðµÂÆìϹ«Ë¾£©Òý½øYescarta (axicabtagene ciloleucel) ÔÚÖйú¾ÙÐÐÊÖÒÕתÒÆ£¬£¬£¬£¬£¬£¬²¢»ñÊÚȨÔÚÖйú¾ÙÐÐÍâµØ»¯Éú²úµÄ°ÐÏòÈËCD19×ÔÌåCAR-Tϸ°ûÖÎÁƲúÆ·¡£¡£¡£¡£¡£¡£ÆäÓÃÓÚÖÎÁƼÈÍù½ÓÊܶþÏß»òÒÔÉÏϵͳÐÔÖÎÁƺ󸴷¢»òÄÑÖÎÐÔ´óBϸ°ûÁÜ°ÍÁö³ÉÈË»¼Õߣ¨°üÀ¨ÃÖÂþÐÔ´óBϸ°ûÁÜ°ÍÁö·ÇÌØÖ¸ÐÍ¡¢Ô­·¢ÐÔ×ݸô´óBϸ°ûÁÜ°ÍÁö¡¢¸ß¼¶±ðBϸ°ûÁÜ°ÍÁöºÍÂËÅÝÐÔÁÜ°ÍÁöת»¯µÄÃÖÂþ´óBϸ°ûÁÜ°ÍÁö£©µÄÐÂÒ©ÉÏÊÐÉêÇëÒÑÓÚ2021Äê6Ô»ñµÃNMPAÅú×¼ÉÏÊС£¡£¡£¡£¡£¡£

¹ØÓÚYescarta?

YescartaÒÑÓÚ2017Äê10ÔÂ18ÈÕ»ñµÃÃÀ¹úFDAÅú×¼ÉÏÊУ¬£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁƸ´¾ÙÊÂÖÎÐÔ´óBϸ°ûÁÜ°ÍÁö³ÉÈË»¼Õߣ¬£¬£¬£¬£¬£¬°üÀ¨ÃÖÂþÐÔ´óBϸ°ûÁÜ°ÍÁö£¨DLBCL£©·ÇÌØÖ¸ÐÍ¡¢Ô­·¢ÐÔ×ݸôBϸ°ûÁÜ°ÍÁö£¨PMBCL£©¡¢¸ß¼¶±ðBϸ°ûÁÜ°ÍÁöºÍÂËÅÝÁÜ°ÍÁöת»¯µÄDLBCL£¬£¬£¬£¬£¬£¬ÊÇÃÀ¹úFDAÅú×¼µÄÊ׿îÕë¶ÔÌض¨·Ç»ôÆæ½ðÁÜ°ÍÁöµÄCAR-Tϸ°ûÒ©Îï¡£¡£¡£¡£¡£¡£

2021Äê3ÔÂ5ÈÕ£¬£¬£¬£¬£¬£¬ÆäÓÃÓÚÖÎÁƸ´·¢/ÄÑÖÎÐÔÂËÅÝÐÔÁÜ°ÍÁö£¨FL£©³ÉÈË»¼ÕßµÄÀ©Õ¹Ë³Ó¦Ö¢ÉêÇë»ñµÃÃÀ¹úFDA¼ÓËÙÅú×¼£¬£¬£¬£¬£¬£¬³ÉΪȫÇòÊ׸ö»ñÅúÉÏÊÐÓÃÓÚFLµÄCAR-Tϸ°ûÖÎÁƲúÆ·¡£¡£¡£¡£¡£¡£Æ¾Ö¤ZUMA-5µ¥±Û¡¢¿ª·Å±êÇ©¡¢¶àÖÐÐÄÊÔÑéЧ¹û£¬£¬£¬£¬£¬£¬ÖÐλËæ·Ãʱ¼äµÖ´ï17.5¸öÔÂʱ£¬£¬£¬£¬£¬£¬ÁÆЧ¿ÉÆÀ¹ÀµÄ104Àý¶èÐÔ·Ç»ôÆæ½ðÁÜ°ÍÁö»¼ÕßµÄ×Ü»º½âÂÊ£¨ORR£©µÖ´ï92%£¬£¬£¬£¬£¬£¬ÍêÈ«»º½âÂÊ(CR)µÖ´ï76%£¬£¬£¬£¬£¬£¬ÆäÖÐÂËÅÝÁÜ°ÍÁö»¼ÕßµÄORRΪ94%£¬£¬£¬£¬£¬£¬CRµÖ´ï80%£¬£¬£¬£¬£¬£¬ÖÐλDOR¡¢PFS¡¢OSÉÐδµÖ´ï£¬£¬£¬£¬£¬£¬64%µÄFL»¼ÕßÔÚÊý¾Ý×èֹʱÈÔ¼á³Ö»º½â£¬£¬£¬£¬£¬£¬ZUMA-5ÖÐδ·¢Ã÷еÄÓëAxi-CelÏà¹ØµÄ²»Á¼ÊÂÎñ2¡£¡£¡£¡£¡£¡£

¹ØÓÚÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾¿­ÌØ

ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾¿­ÌØÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾ÎªÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾ÓëÃÀ¹úKiteµÄºÏÓªÆóÒµ£¬£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚÖ×Áöϸ°ûÖÎÁƲúÆ·µÄÑз¢Á¢ÒìºÍ¹¤Òµ»¯¡¢ÉÌÒµ»¯¡¢¹æ·¶»¯Éú³¤£¬£¬£¬£¬£¬£¬Ô츣Öйú»¼Õß¡£¡£¡£¡£¡£¡£¹«Ë¾×ܲ¿Î»ÓÚÉϺ£ÕŽ­¸ß¿Æ¼¼Ô°Çø£¬£¬£¬£¬£¬£¬10000ƽ·½Ã×µÄCAR-T¹¤Òµ»¯Éú²ú»ùµØÒÑÔÚÕŽ­Á¢ÒìÒ©¹¤Òµ»ùµØ½¨³É²¢ÕýʽÆôÓᣡ£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬¹«Ë¾»¹ÓµÓÐ2000ƽÃ×µÄϸ°ûÖÎÁÆÑз¢ÖÐÐĺÍÁ¢ÒìÈ˲ÅÍŶӣ¬£¬£¬£¬£¬£¬Í¨¹ý×ÔÖ÷Á¢ÒìºÍ¹ú¼ÊÏàÖú£¬£¬£¬£¬£¬£¬×¨×¢ CAR-TÔçÆÚÑз¢ºÍÁÙ´²Ñ­Ö¤½×¶ÎµÄÏîÄ¿£¬£¬£¬£¬£¬£¬´òÔì¿ÉÒ»Á¬µÄÁ¢ÒìÑз¢¹ÜÏß¡£¡£¡£¡£¡£¡£

ÓйØÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾¿­Ìظü¶àÐÅÏ¢£¬£¬£¬£¬£¬£¬Çë»á¼ûwww.fosunkitebio.com

Êý¾ÝȪԴ£º
1.? ? ?NCCN Guideline V1. 2020 B-cell Lymphomas
2.? ? ?Jacobson CA, et al. 2020 ASH Oral Abstract 700.